KYNB logo

KYNTRA BIO INC

KYNBNASDAQ
πŸ† #4910 by market capUS Equity
$1.71β–Ό $0.12 (βˆ’6.56%)
Market closed Β· at close
πŸ””
Track KYNB
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.6%
7dβ–Ό 52.5%
14dβ–Ό 54.9%
30dβ–Ό 64.7%
ytdβ–Ό 80.5%
1yβ–Ό 79.9%
🏦Market Cap
$7M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-78.3%
Declining
πŸ“ŠGross Margin
19.6%
Thin
πŸ’΅FCF Margin
-913.6%
Thin
βš–οΈP/S Ratio
1.2x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.71 – $1.75
52-Week Range
$1.54 – $10.47
Volume (shares)
200
Avg Volume (shares)
β€”
Shares Outstanding
4.0M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
β€”
P/E Ratio
0.2
P/S Ratio
1.2x
EPS (TTM)
$8.61
Dividend Yield
0.00%
Dilution (1yr)
+0.2%
KYNB logo

KYNTRA BIO INC

KYNB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6Mβ–Ό βˆ’78.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.4%β–² +92.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$46Mβ–Ό βˆ’69.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–Ό βˆ’96.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.0Mβ–² +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$48Mβ–² +$70M YoY
StockOtter Β· stockotter.space

About KYNTRA BIO INC

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.